Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$144.82
+0.6%
$136.87
$77.58
$156.92
$355.10B0.2110.74 million shs7.41 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$43.47
+0.9%
$47.37
$35.12
$64.16
$192.31B0.7410.24 million shs6.54 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$27.74
+0.1%
$26.43
$23.58
$29.21
$157.99B0.3431.64 million shs28.22 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.00%-4.22%+6.07%+25.21%+73.79%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.00%-7.63%-6.27%-1.87%-21.67%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%-2.57%+3.42%+6.46%+15.81%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$144.82
+0.6%
$136.87
$77.58
$156.92
$355.10B0.2110.74 million shs7.41 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$43.47
+0.9%
$47.37
$35.12
$64.16
$192.31B0.7410.24 million shs6.54 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$27.74
+0.1%
$26.43
$23.58
$29.21
$157.99B0.3431.64 million shs28.22 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.00%-4.22%+6.07%+25.21%+73.79%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.00%-7.63%-6.27%-1.87%-21.67%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%-2.57%+3.42%+6.46%+15.81%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.68
Moderate Buy$151.324.49% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.16
Hold$64.9449.38% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.19
Hold$28.392.34% Upside

Current Analyst Ratings Breakdown

Latest NVO, PFE, and MRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/10/2026
Pfizer Inc. stock logo
PFE
Pfizer
Boost Price TargetHold$28.00 ➝ $30.00
9/10/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Reiterated RatingHold
9/10/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetBuy$150.00 ➝ $172.00
9/9/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetOutperform$127.00 ➝ $161.00
9/8/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetBuy$146.00 ➝ $170.00
9/4/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetOverweight$150.00 ➝ $170.00
8/31/2026
Pfizer Inc. stock logo
PFE
Pfizer
UpgradeHold (C-)Hold (C)
8/27/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
DowngradeHoldSell
8/25/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
UpgradeHold (C-)Hold (C)
8/25/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetOutperform$155.00 ➝ $180.00
8/25/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetBuy$145.00 ➝ $170.00
(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.01B5.50$11.49 per share12.60$21.22 per share6.82
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.80B4.15$4.73 per share9.19$6.58 per share6.61
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.53$4.40 per share6.30$15.26 per share1.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$1.25115.8614.996.264.77%16.73%6.13%10/29/2026 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$4.0910.6312.711.4535.36%58.61%20.91%11/4/2026 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$0.7636.509.441.866.80%19.63%8.46%11/3/2026 (Estimated)

Latest NVO, PFE, and MRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.77$0.96+$0.19$0.72$10.89 billion$11.98 billion
8/4/2026Q2 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$0.26-$0.13+$0.13-$0.54$16.37 billion$16.61 billion
8/4/2026Q2 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.6820$0.77+$0.0880-$0.04$14.40 billion$15.03 billion
6/30/2026Q2 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
N/A$0.9440N/A$0.72N/A$11.98 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.402.35%+5.75%272.00%14 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.821.89%+21.74%20.05%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.20%-13.20%226.32%16 Years

Latest NVO, PFE, and MRK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/29/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.852.61%9/15/20269/15/202610/7/2026
6/24/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.01%7/24/20267/24/20269/1/2026
8/5/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.57862.58%8/17/20268/17/20268/25/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.22
1.32
1.10
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.55
0.87
0.66
Pfizer Inc. stock logo
PFE
Pfizer
0.71
1.27
0.96

Institutional Ownership

CompanyInstitutional Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.46 billionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable

Recent News About These Companies

Can Pfizer Overcome Its COVID and Patent Cliff Headwinds?
4 High-Yield Dividend Stocks Worth Having in Your Roth IRA
Can Pfizer Overcome Its COVID and Patent Cliff Headwinds?
Pfizer’s 6% Yield Masks a Fragile Dividend Story
Pfizer's 6% Yield Masks a Fragile Dividend Story
Pfizer (NYSE:PFE) Upgraded at Wall Street Zen
Pfizer (NYSE:PFE) Rating Increased to Buy at Wall Street Zen
Pfizer Stock Eyes New Boom With Obesity And Alopecia Bets
Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI
Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI
135,800 Shares in Pfizer Inc. $PFE Acquired by WINTON GROUP Ltd
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?
Pfizer: Firing On All Cylinders

New MarketBeat Followers Over Time

Media Sentiment Over Time

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$144.82 +0.89 (+0.62%)
Closing price 03:59 PM Eastern
Extended Trading
$144.69 -0.13 (-0.09%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$43.47 +0.40 (+0.93%)
Closing price 03:59 PM Eastern
Extended Trading
$43.62 +0.14 (+0.33%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Pfizer stock logo

Pfizer NYSE:PFE

$27.74 +0.02 (+0.07%)
Closing price 03:59 PM Eastern
Extended Trading
$27.56 -0.18 (-0.67%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.